NO20034647L - Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander - Google Patents

Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander

Info

Publication number
NO20034647L
NO20034647L NO20034647A NO20034647A NO20034647L NO 20034647 L NO20034647 L NO 20034647L NO 20034647 A NO20034647 A NO 20034647A NO 20034647 A NO20034647 A NO 20034647A NO 20034647 L NO20034647 L NO 20034647L
Authority
NO
Norway
Prior art keywords
hydroxyclylalkoxy
alkylaminobenzazole
hydroxytryptamine
alkyloxy
ligands
Prior art date
Application number
NO20034647A
Other languages
English (en)
Other versions
NO20034647D0 (no
Inventor
Ping Zhou
Yanfang Li
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20034647D0 publication Critical patent/NO20034647D0/no
Publication of NO20034647L publication Critical patent/NO20034647L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20034647A 2001-04-20 2003-10-17 Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander NO20034647L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28564401P 2001-04-20 2001-04-20
PCT/US2002/012512 WO2002085853A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (2)

Publication Number Publication Date
NO20034647D0 NO20034647D0 (no) 2003-10-17
NO20034647L true NO20034647L (no) 2003-11-20

Family

ID=23095117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034647A NO20034647L (no) 2001-04-20 2003-10-17 Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander

Country Status (17)

Country Link
US (2) US6831094B2 (no)
EP (1) EP1392682A2 (no)
JP (1) JP2004526781A (no)
KR (1) KR20030088507A (no)
CN (1) CN1293073C (no)
AR (1) AR034588A1 (no)
AU (1) AU2002309585B2 (no)
BR (1) BR0209047A (no)
CA (1) CA2444036A1 (no)
EA (1) EA200301143A1 (no)
HU (1) HUP0303801A2 (no)
IL (1) IL158448A0 (no)
MX (1) MXPA03009490A (no)
NO (1) NO20034647L (no)
PL (1) PL366639A1 (no)
WO (1) WO2002085853A2 (no)
ZA (1) ZA200309009B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1513809A1 (en) * 2002-06-05 2005-03-16 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
TWI284124B (en) 2002-12-03 2007-07-21 Hoffmann La Roche Aminoalkoxyindoles
PL378120A1 (pl) * 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
EP1915348A1 (en) * 2005-08-15 2008-04-30 Wyeth a Corporation of the State of Delaware Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20080039994A (ko) * 2005-08-15 2008-05-07 와이어쓰 5-하이드록시트립타민-6 리간드로서의치환된-3-설포닐인다졸
CN101432274A (zh) * 2006-04-05 2009-05-13 惠氏公司 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
CA2650082A1 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
WO2009006267A2 (en) * 2007-06-28 2009-01-08 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
DK2624696T3 (en) 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
TW288010B (no) * 1992-03-05 1996-10-11 Pfizer
WO1995003298A1 (en) 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (ja) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
GB9523462D0 (en) 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
AU7526798A (en) * 1997-04-18 1998-11-27 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
EP1196380A2 (en) * 1999-07-15 2002-04-17 NPS Allelix Corp. Indoles and indazoles for the treatment of migraine
IL156517A0 (en) * 2000-12-22 2004-01-04 Wyeth Corp Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
PL378120A1 (pl) * 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy

Also Published As

Publication number Publication date
US6831094B2 (en) 2004-12-14
WO2002085853A2 (en) 2002-10-31
KR20030088507A (ko) 2003-11-19
NO20034647D0 (no) 2003-10-17
CN1293073C (zh) 2007-01-03
US20030078286A1 (en) 2003-04-24
PL366639A1 (en) 2005-02-07
US20050065185A1 (en) 2005-03-24
BR0209047A (pt) 2004-08-10
WO2002085853A3 (en) 2002-12-19
EP1392682A2 (en) 2004-03-03
HUP0303801A2 (hu) 2004-03-01
EA200301143A1 (ru) 2004-02-26
AU2002309585B2 (en) 2008-01-31
MXPA03009490A (es) 2004-02-12
IL158448A0 (en) 2004-05-12
JP2004526781A (ja) 2004-09-02
AR034588A1 (es) 2004-03-03
CA2444036A1 (en) 2002-10-31
ZA200309009B (en) 2005-02-21
CN1518548A (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
NO20034648D0 (no) Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander
DK1353904T3 (da) 1-Aryl- eller 1-alkylsulfonylbenzazolderivater som 5-hydroxytryptamin-6-ligander
NO20031977L (no) 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler som 5- hydroksytryptamin-6-ligander
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1355904T3 (da) Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
NO20032531D0 (no) Tetralon-derivater som antitumormidler
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
DK1509522T3 (da) 1-(Aminoalkyl)-3-sulfonylazaindoler som 5-hydroxytryptamin-6-ligander
ATE319451T1 (de) Tetrahydrochinolin-derivate
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20041316L (no) Tiofen- og tiazoisulfonamider som antineoplastiske midler
NO20034647D0 (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
NO20033234L (no) Karotenoider som antihypertensjonsmidler
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE60220799D1 (de) Hypoglykämisches mittel
DE60136966D1 (de) Pflanzenstärkendes mittel
DE60202381D1 (de) Paroxetin-n-formyl-derivate
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt
DK1177185T3 (da) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
DK1287001T3 (da) Thiophenderivater, der er egnede som anticancermidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application